Business Wire

NY-LUMEN

9.12.2021 16:02:32 CET | Business Wire | Press release

Share
Lumen Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

CB Insights named Lumen , the company behind the world’s first metabolism measurement device through the breath, to its third annual Digital Health 150 , which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005668/en/

The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016, and includes startups at various investment stages of development, from early-stage to well-funded unicorns . Companies this year include startups working on data integration & analytics, hybrid virtual / in-person care, digital therapeutics, clinical intelligence, and more.

“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year's class has seen more than 20 exits, raised an additional $18.6B in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”

“We’re thrilled to be recognized as an innovative leader in the digital health space by CB Insights. Our mission is to make people metabolically healthier through our groundbreaking technology as we grow towards becoming the largest health platform of 1 million metabolism measurements a month,” says Daniel Tal Mor, CEO and Co-founder of Lumen.

Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores , CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.

2021 Digital Health 150 Investment Highlights:

  • Unicorns : 17 of the 150 companies (11%) are valued at or above $1B as of their latest funding rounds.
  • Funding trends : In 2021 year-to-date (YTD), these 150 private companies have raised $9.2B in equity funding across 153 deals (as of 11/19/21).
  • Mega-rounds : Since 2020, there have been 39 mega-round ($100M+) equity investments to this year’s Digital Health 150, with 31 (79%) of them taking place in 2021 YTD.
  • Global representation : 23% of the 2021 Digital Health 150 are based outside the US. After the US, the UK is home to the most Digital Health 150 companies (9), followed by India (4). This year’s winners are based in 18 countries, including China, Israel, Nigeria, Germany, Argentina, and New Zealand.
  • Top VC investor: General Catalyst is the most active investor in this year’s Digital Health 150 companies, having invested in 39 deals since 2016.

About CB Insights
CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com .

About Lumen

Lumen helps people improve their health and fitness through technology on the forefront of personalized nutrition and metabolism. Conceived and designed by twin sisters, physiology PhDs and Ironman winners, Lumen harnesses the power of our breath to measure metabolism, which is closely linked to weight, fitness and personal health. The Lumen device measures metabolism in a single breath, in less than a minute, which previously was only possible through an hour-long lab test. Available at Lumen.me, Lumen devices ship globally, with the app available on the Apple App Store and Google Play. Lumen is headquartered in Israel, with offices in the United States.

Link - https://www.lumen.me/

Link:

ClickThru

Social Media:

https://www.facebook.com/Lumen.me/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release

Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye